Clinical Trial Detail

NCT ID NCT02109016
Title A Study to Assess the Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGFR1-driven Lung Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Clovis Oncology, Inc.
Indications

non-small cell lung carcinoma

Therapies

Lucitanib

Age Groups: adult

Additional content available in CKB BOOST